CBS 2019
CBSMD教育中心
中 文

Other Relevant Articles

Abstract

Recommended Article

A Test in Context: E/A and E/e' to Assess Diastolic Dysfunction and LV Filling Pressure A randomized multicentre trial to compare revascularization with optimal medical therapy for the treatment of chronic total coronary occlusions Pulmonary Artery Pressure-Guided Management of Patients With Heart Failure and Reduced Ejection Fraction Effect of Aspirin on All-Cause Mortality in the Healthy Elderly Residual Inflammatory Risk in Patients With Low LDL Cholesterol Levels Undergoing Percutaneous Coronary Intervention When high‐volume PCI operators in high‐volume hospitals move to lower volume hospitals—Do they still maintain high volume and quality of outcomes? ACCF/SCAI/STS/AATS/AHA/ASNC 2009 Appropriateness Criteria for Coronary Revascularization: A Report by the American College of Cardiology Foundation Appropriateness Criteria Task Force, Society for Cardiovascular Angiography and Interventions, Society of Thoracic Surgeons, American Association for Thoracic Surgery, American Heart Association, and the American Society of Nuclear Cardiology Endorsed by the American Society of Echocardiography, the Heart Failure Society of America, and the Society of Cardiovascular Computed Tomography Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association

Original ResearchVolume 114, August 2021, Pages 11-24

JOURNAL:Trends Food Sci Technol. Article Link

Potential protective mechanisms of green tea polyphenol EGCG against COVID-19

Y Zhang, B Wernly, ZCh Zhou et al. Keywords: COVID-19; prevention; green tea; EGCG

ABSTRACT

BACKGROUND - The world is in the midst of the COVID-19 pandemic. In this comprehensive review, we discuss the potential protective effects of ()-epigallocatechin-3-gallate (EGCG), a major constituent of green tea, against COVID-19.


SCOPE AND APPROACH - Information from literature of clinical symptoms and molecular pathology of COVID-19 as well as relevant publications in which EGCG shows potential protective activities against COVID-19 is integrated and evaluated.


KEY FINDINGS AND CONCLUSIONS - EGCG, via activating Nrf2, can suppress ACE2 (a cellular receptor for SARS-CoV-2) and TMPRSS2, which mediate cell entry of the virus. Through inhibition of SARS-CoV-2 main protease, EGCG may inhibit viral reproduction. EGCG via its broad antioxidant activity may protect against SARS-CoV-2 evoked mitochondrial ROS (which promote SARS-CoV-2 replication) and against ROS burst inflicted by neutrophil extracellular traps. By suppressing ER-resident GRP78 activity and expression, EGCG can potentially inhibit SARS-CoV-2 life cycle. EGCG also shows protective effects against 1) cytokine storm-associated acute lung injury/acute respiratory distress syndrome, 2) thrombosis via suppressing tissue factors and activating platelets, 3) sepsis by inactivating redox-sensitive HMGB1, and 4) lung fibrosis through augmenting Nrf2 and suppressing NF-κB. These activities remain to be further substantiated in animals and humans. The possible concerted actions of EGCG suggest the importance of further studies on the prevention and treatment of COVID-19 in humans. These results also call for epidemiological studies on potential preventive effects of green tea drinking on COVID-19.